Finanse i rynek · 15.10.2026

Neuroendocrine Prostate Cancer Market to Witness Growth at a 25% CAGR by 2036 Due to the Emergence of Emerging agents, including DLL3-targeted Therapies, ADCs, BsAbs, CAR-Ts, Aurora Kinase Inhibitors, and EZH2 Inhibitors

The neuroendocrine prostate cancer market is expected to grow steadily, driven by the rising recognition of NEPC as an aggressive and treatment-resistant form of prostate cancer.